3 entities actively seeking solutions — right now.

Pursuit detects live signals from MD Anderson ($30M cell therapy funding), CPRIT (clinical trial expansion), and UT System ($70M research campus)—three of thousands seeking Trillium solutions. Win before RFPs close; early signal access is your competitive edge.

See the Full Platform

See 3 opportunities ↓

SLED entities monitored

110K+

Documents processed monthly

3M+

Before RFPs drop

6–18mo

Earlier than the competition

92 days

From 110K+ entities monitored

Pre-RFP signals for

<div class='ecard'><div class='ecard-header'><div><div class='ecard-name'>Cancer Prevention and Research Institute of Texas</div><div class='ecard-meta'>County Government · TX</div></div><div class='ecard-header-right'><span class='badge badge-watch'>Watch</span></div></div><div class='ecard-signals'><div class='signal-item'><div class='signal-title'>Phase 2 trial for advanced esophageal and gastric adenocarcinoma</div><div class='signal-body-text'>Cancer Prevention and Research Institute of Texas is tracking a Phase 2 clinical trial at University of Wisconsin Carbone Cancer Center testing combination chemotherapy (5-Fluorouracil, Oxaliplatin, Liposomal Irinotecan, and Trastuzumab) for advanced esophageal and gastric adenocarcinoma, signaling interest in emerging oncology treatment approaches. This trial activity suggests potential demand for CD47-targeting immuno-oncology biologics to enhance response rates in difficult-to-treat cancers. No RFP has been issued; this is pre-solicitation intelligence.</div></div><div class='signal-item'><div class='signal-title'>Immunotherapy combination improves outcomes for gastric cancer patients</div><div class='signal-body-text'>Cancer Prevention and Research Institute of Texas is allocating resources to monitor advanced gastric and esophageal cancer treatment pathways, indicating budget commitment to precision oncology outcomes. This trial investment signals organizational readiness to adopt combination therapies that improve patient survival metrics and reduce treatment failure costs.</div></div></div><div class='ecard-contacts'><div class='ecard-contacts-label'>Key Contacts · 5 verified by Pursuit</div><div class='contact-list'><div class='contact-row'><div class='contact-info'><span class='contact-name'>Patty Moore</span><span class='contact-title'>Director of Academic Research</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Patricia Moore</span><span class='contact-title'>Director of Academic Research</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Myriam Casillas</span><span class='contact-title'>Program Manager for Academic Research</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Jasmin Giles</span><span class='contact-title'>Program Manager for Product Development</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Abria Magee</span><span class='contact-title'>Program Manager for Product Development</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div></div></div><div class='ecard-footer'><a class='ecard-source-link' href='https://app.pursuit.us/d/eyJ2IjoxLCJvIjoiNjZlOTI4MDg5OWM5NzViYjA1N2M1ZWUxIiwidSI6ImFIUjBjSE02THk5M2QzY3VZM0J5YVhRdWRHVjRZWE11WjI5MkwyMWxaR2xoTDJoek5HcDJNWHBtTDI5algzQmhZMnRsZEY4d09ERTVNakF5Tmk1d1pHWT0iLCJraWQiOiIxIiwicCI6MzgxLCJjIjozNTU0fQ.fsZX0pxJhJoZk0L0dOaw4A7yaR0EK1vnEnV5D1BE4A4' target='_blank'>View source · 2026-08-19</a><span class='ecard-timing'>⏱ Pre-RFP — no solicitation issued</span></div></div> <div class='ecard'><div class='ecard-header'><div><div class='ecard-name'>The University of Texas MD Anderson Cancer Center</div><div class='ecard-meta'>County Government · TX</div></div><div class='ecard-header-right'><span class='badge badge-hot'>High Intent</span></div></div><div class='ecard-signals'><div class='signal-item'><div class='signal-title'>$30 million funds Institute for Cell Therapy Discovery and Innovation</div><div class='signal-body-text'>The University of Texas MD Anderson Cancer Center is planning a $30 million investment to expand its oncology research capabilities through the Institute for Cell Therapy Discovery and Innovation. This expansion signals demand for CD47-targeting immuno-oncology biologics to support advanced cell therapy research programs. No RFP has been issued; this is pre-solicitation intelligence.</div></div><div class='signal-item'><div class='signal-title'>Cancer center accelerates CD47-targeting immunotherapy development</div><div class='signal-body-text'>The University of Texas MD Anderson Cancer Center's $30 million allocation reflects institutional commitment to accelerating cell therapy commercialization timelines, directly impacting competitive positioning in precision oncology markets. This budget commitment creates procurement momentum for specialized biologics suppliers positioned to support scaled manufacturing and clinical validation workflows.</div></div></div><div class='ecard-contacts'><div class='ecard-contacts-label'>Key Contacts · 5 verified by Pursuit</div><div class='contact-list'><div class='contact-row'><div class='contact-info'><span class='contact-name'>Katy Rezvani</span><span class='contact-title'>Professor</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Albert Koong</span><span class='contact-title'>Senior Vice President, Chief Scientific Officer</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Kathleen Schmeler</span><span class='contact-title'>Executive Director of Global Oncology</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>David Jaffray</span><span class='contact-title'>Senior Vice President, Chief Technology and Digital Officer</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Jeffrey Lee</span><span class='contact-title'>Executive Vice President, Chief Physician Executive</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div></div></div><div class='ecard-footer'><a class='ecard-source-link' href='https://app.pursuit.us/d/eyJ2IjoxLCJvIjoiNjVkNjhjNTJhYmFjY2E3MTNjNzllMDU1IiwidSI6ImFIUjBjSE02THk5M2QzY3ViV1JoYm1SbGNuTnZiaTV2Y21jdlkyOXVkR1Z1ZEM5a1lXMHZiV1JoYm1SbGNuTnZiaTlrYjJOMWJXVnVkSE12WVdKdmRYUXRiV1F0WVc1a1pYSnpiMjR2WVdKdmRYUXRkWE12ZFhRdGMzbHpkR1Z0TFhKbGNHOXlkSE12VEdWbmFYTnNZWFJwZG1VbE1qQkJjSEJ5YjNCeWFXRjBhVzl1Y3lVeU1GSmxjWFZsYzNRdlpua3lNREkyTFRJd01qY3RiR1ZuYVhOc1lYUnBkbVV0WVhCd2NtOXdjbWxoZEdsdmJuTXRjbVZ4ZFdWemRDNXdaR1k9Iiwia2lkIjoiMSIsInAiOjE0LCJjIjozNTU0fQ.LzUFsFEnvzhbfo8w5giKq_mDjlxFwyZqxZL3l-O7F4I' target='_blank'>View source · 2026-08-31</a><span class='ecard-timing'>⏱ Pre-RFP — no solicitation issued</span></div></div> <div class='ecard'><div class='ecard-header'><div><div class='ecard-name'>University of Texas System</div><div class='ecard-meta'>County Government · TX</div></div><div class='ecard-header-right'><span class='badge badge-watch'>Watch</span></div></div><div class='ecard-signals'><div class='signal-item'><div class='signal-title'>Received $70 million to build integrated education research space</div><div class='signal-body-text'>UT MD Anderson has received $70 million in Capital Construction Assistance to build an integrated education and research space on the Legacy Campus, signaling expansion of research infrastructure and clinical capabilities. This facility development creates demand for advanced immuno-oncology biologics to support expanded research and treatment programs. No RFP has been issued; this is pre-solicitation intelligence.</div></div><div class='signal-item'><div class='signal-title'>Immunotherapy research accelerates with targeted cancer cell approach</div><div class='signal-body-text'>The University of Texas System's $70 million capital investment signals budget commitment to modernize research infrastructure, creating procurement momentum for specialized biologics vendors. UT MD Anderson's facility expansion requires validated therapeutic partners to populate new research and clinical pipelines, positioning early-stage suppliers for long-term institutional partnerships.</div></div></div><div class='ecard-contacts'><div class='ecard-contacts-label'>Key Contacts · 5 verified by Pursuit</div><div class='contact-list'><div class='contact-row'><div class='contact-info'><span class='contact-name'>Brian Smith</span><span class='contact-title'>Senior Vice President and Chief Financial Officer</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Terry Hull</span><span class='contact-title'>Associate Vice Chancellor and Chief Financial Officer</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Derek Horton</span><span class='contact-title'>Associate Vice Chancellor and Deputy Chief Financial Officer</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Jamie Frey</span><span class='contact-title'>Director of Finance</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div><div class='contact-row'><div class='contact-info'><span class='contact-name'>Geoffrey Richards</span><span class='contact-title'>Executive Director</span></div><div class='contact-data-hints'><span class='data-hint'>Email</span><span class='data-hint'>Phone</span></div></div></div></div><div class='ecard-footer'><a class='ecard-source-link' href='https://app.pursuit.us/d/eyJ2IjoxLCJvIjoiNmEyMjBhMzVjZDJkMjBkNjA0YWRkZDE5IiwidSI6ImFIUjBjSE02THk5M2QzY3VkWFJ6ZVhOMFpXMHVaV1IxTDNOcGRHVnpMMlJsWm1GMWJIUXZabWxzWlhNdlpHOWpkVzFsYm5SekwzVjBMWE41YzNSbGJTMXlaWEJ2Y25Sekx6SXdNall2ZFhRdGMzbHpkR1Z0TFd4bFoybHpiR0YwYVhabExXRndjSEp2Y0hKcFlYUnBiMjV6TFhKbGNYVmxjM1J6TFhWMExXMHRaQzFoYm1SbGNuTnZiaTFqWVc1alpYSXRZMlZ1ZEdWeUwzVnVhWFpsY25OcGRIa3RiMll0ZEdWNFlYTXRiV1F0WVc1a1pYSnpiMjR0WTJGdVkyVnlMV05sYm5SbGNpMXNZWEl0WVhWbmRYTjBMVEl3TWpZdWNHUm0iLCJraWQiOiIxIiwicCI6MTIsImMiOjM1NTR9.EeIVGQLE43lSArlb4rhYZM7-sOHIdzzwfejHrcL1V7A' target='_blank'>View source · 2028-01-01</a><span class='ecard-timing'>⏱ Pre-RFP — no solicitation issued</span></div></div>

Why needs Pursuit

92 days

Earlier to every deal

Pursuit customers engage an average of 92 days before the competition finds the same opportunity — giving 's team time to shape the deal and show up as the trusted partner before any RFP is written.

2.5M

Documents processed monthly

Pursuit reads 2.5 million government documents monthly — meeting minutes, strategic plans, budget filings, and FOIA records — surfacing the signals that matter to 's ICP before they become public solicitations.

73%

Of deals are decided before the RFP drops

By the time a formal solicitation is published, the winning vendor is usually already in the room. Pursuit gets your team there first — with the context, contacts, and credibility to shape the deal before anyone else knows it exists.

SCHEDULE DEMO

See Trillium Therapeutics Inc's full pipeline in Pursuit

These three are a sample of what Pursuit surfaces for Trillium Therapeutics Inc. across 110,000+ entities matched to your ICP. Book time to see your full ICP‑matched opportunity list — with contacts, signals, and source documents for every account.

TRUSTED BY